Peptide·plain sequence-like

Plecanatide

ATLPC0019952

NDECELCVNVACTGCL

Routes

Compare in workbench Download release API JSON

Length
16 aa
Monoisotopic mass
1684.7 Da
Net charge @ pH 7.4
-3.00
Isoelectric point
3.42
GRAVY
0.575

Coveragecounts only · not riskATLPC0019952

Measurements
7
Endpoints
5
Domains
2/5
Products
1

No matrix stability evidence
No clearance evidence
Product-level review pending
2 liability motifs

Jump to domain

Open the matching evidence section below

All evidence index · 7

Exposure / Absorption

4 measurements

Distribution / Barrier

3 measurements

Metabolic & Proteolytic Stability

No evidence

Excretion / Persistence

No evidence

Toxicity / Safety

No evidence

Sequence & molecular identity

1 forms

Reviewed sequence, peptidoform forms, chemical representation, 3D references, and covalent topology used to interpret this peptide identity.

Sequence & peptidoform

Identity summaryCanonical sequence only

Identity status: Canonical sequence only
Residues: 16
Peptidoform features: 0
Documented molecular forms: 1
Representations: 2

Documented molecular forms1 form linked to this peptide identity

Form	Topology	Modifications	Connections	Representations	Measurements
ATLPF0030105	—	3	2	1	5

Residue view

Residue display

16 residues

N1D2E3C4E5L6C7V8N9V10A11C12T13G14C15L16

Side-chain classNonpolarPolarBasic (+)Acidic (−)Modified

Soft tints mark standard side-chain classes for scanning. Primary emphasis is reserved for reported modifications, termini, secondary-structure tracks, and topology links.

Peptidoform features

Features are shown only when a reported notation or topology record supports them.

No terminal modification, residue-level marker, disulfide, staple, coordination, or other topology signal is currently available.

Structure & chemistry

Chemical representationsequence / HELM only

Representation class

How the current release can interpret this identity chemically.

plain sequence-like

Parent-residue sequence

Residue string used for positional interpretation when available.

NDECELCVNVACTGCL

HELM

Polymer notation for modified peptide representation when available.

Not available

SMILES

Chemical graph string used for atom-level 2D depiction when available.

Not available

No atom-level graph

A reviewed SMILES is required before a 2D molecular depiction can be shown. Sequence and HELM remain useful for identity interpretation, but they do not replace a chemical graph.

3D structure referencesnone attached

3D structure not available

A 3D structure isn't available for this peptide in the current release. Chemistry and topology fields remain available when represented by sequence, HELM, or SMILES.

Covalent topology & modifications1 signal

Feature	Positions	Interpretation	Link
Form-level topology	ATLPF0030105	Multiple-disulfide form. Residue-level connection endpoints are shown separately when available.	Not linked

Physicochemical profile

4 descriptors

Computed sequence-derived descriptors and any measured physicochemical evidence such as lipophilicity. Computed values are interpretation aids, not experimental ADMET measurements.

Core descriptors16 aa · pI 3.4 · GRAVY 0.57

Length: 16 aa
Monoisotopic mass: 1684.66 Da
Average mass: 1685.92 Da
Net charge at pH 7.4: -3.00
Estimated pI: 3.42
GRAVY: 0.575
KD-positive residues: 56.3%
Aromatic residues: 0.0%

Developability interpretation

Ionization context: pH 7.4 separated from pI
Hydrophobicity balance: Leans hydrophobic
Amphipathic moment (μH): 0.68
Computation boundary: Standard-sequence only

Charge & residue composition

pH charge context

Modeled net charge across common formulation and assay pH checkpoints.

pH 2

0.95

pH 5

-2.67

pH 6

-2.98

pH 7.4

-3.35

pH 9

-6.75

pH 12

-8.00

Residue-class composition

Grouped composition is often more interpretable than a long amino-acid list.

Acidic (D,E)

3 · 18.8%

Polar uncharged (N,Q,S,T)

3 · 18.8%

Hydrophobic aliphatic (A,V,I,L,M)

5 · 31.3%

Conformational / sulfur (G,P,C)

5 · 31.3%

Top residues

C425.0%N212.5%E212.5%L212.5%V212.5%A16.3%D16.3%G16.3%

Hydropathy & amphipathic windows

Hydropathy windows

Seven-residue sliding windows expose local patches hidden by whole-sequence GRAVY.

Most hydrophobic window

6-12

LCVNVAC

GRAVY 2.214

Most hydrophilic window

1-7

NDECELC

GRAVY -0.743

10 local hydropathy windows scanned. A local patch is context for solubility, adsorption, and membrane interaction review, not a standalone endpoint.

Amphipathic-window scan

Top alpha-helix hydrophobic-moment windows across 12, 15, 18, and 21 residues.

12 aa window

2-13

DECELCVNVACT

μH 1.07 · charge -3.0

12 aa window

1-12

NDECELCVNVAC

μH 1.05 · charge -3.0

12 aa window

4-15

CELCVNVACTGC

μH 1.00 · charge -1.0

15 aa window

1-15

NDECELCVNVACTGC

μH 0.94 · charge -3.0

15 aa window

2-16

DECELCVNVACTGCL

μH 0.79 · charge -3.0

Sequence-liability cues

Sequence-liability notes

Motifs are review prompts for formulation or CMC interpretation; they are not degradation predictions.

Oxidation-sensitive residues

C · pos 4, 7, 12, 15

Met, Trp, and Cys residues can merit formulation review for oxidation or covalent-state sensitivity.

Cys covalent complexity

C · pos 4, 7, 12, 15

Multiple cysteines can indicate disulfide or free-thiol interpretation requirements.

Alpha-helix amphipathic projection

Helical wheel · Edmundson projection

μ_H = 0.68100°/residue · 16 aa

Hydrophobic moment0.68

Mean K-D hydropathy0.57

Approx. net charge-3

Projection angle100° / residue

The pale sector marks the direction of the hydrophobic face inferred from μ_H. This is a projection assumption, not a measured fold.

HydrophobicAromaticPolarBasic +Acidic −Specialhydrophobic faceμ_H arrow → hydrophobic face

The projection assumes an α-helix conformation; a long μ_H arrow indicates an amphipathic helix, common in antimicrobial peptides.

Method notes

Charge model: side-chain pKa D 3.9, E 4.1, C 8.5, Y 10.1, H 6.5, K 10.8, R 12.5 with EMBOSS termini. pI is estimated by binary search on modeled net charge. Hydropathy uses Kyte-Doolittle values; hydrophobic moment follows the Eisenberg alpha-helix vector-sum convention. When the basis is a parent-residue sequence, modified chemistry is intentionally not inferred.

Computed developability descriptors

Deterministic descriptors computed from the reviewed sequence or chemical structure (RDKit), each anchored to a literature method. These are computed estimates for developability interpretation — not experimental measurements — and are validated against independent reference implementations.

Sequence-derived

Computed from the standard parent-residue sequence; protein-origin metrics defined at any length.

Aliphatic index

91.25

Instability index

86.7

Above 40 — predicted unstable in vitro.

Boman index

0.78 kcal/mol

Molar extinction coefficient (280 nm)

0 M⁻¹·cm⁻¹

A280 (1 g/L) ≈ 0.00 · 250 M⁻¹·cm⁻¹ with 2 disulfides

Structure-derived descriptors are not shown because this identity has no resolved chemical structure (SMILES). This is a known coverage gap for disulfide-rich and unresolved peptidoforms, not a computation error.

Exposure / Absorption

4 records

What evidence describes systemic exposure or absorption?

Evidence records

Complete canonical measurements and observations attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Matched-context analysis

Quantitative results that may be analysed only with scientifically compatible records.

Reported-result review

Qualitative, narrative, or review-first results interpreted in their source context.

Endpoints in scopeBioavailability AUC Cmax

Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis

Quantitative results whose endpoint and context must still be matched before analysis.

Interpret as reported

Qualitative, narrative, or review-first findings preserved in source context.

Supporting context only

Reference, label, clinical, or supporting context for interpretation.

Review before analysis

Records whose present structure does not establish a safe analysis role.

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Bioavailability2 records · 0 matched-context · 2 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	Observation Plecanatide was minimally absorbed with negligible systemic availability following oral administration.	Interpret as reported	human	Result: Qualitative or narrative result · Molecular form: ATLPF0030105 · Route: oral · Plecanatide· 12.3 Pharmacokinetics · bioavailability negligible systemic availability tex... · Source: Primary reference linked	Reference
2	Observation Plecanatide is minimally absorbed with negligible systemic availability following oral administration. Concentrations of plecanatide and its active metabolite in plasma are below the limit of quantitation after an oral dose of 3 mg. Therefore, standard pharmacokinetic parameters such as AUC, maximum concentration (Cmax), and half-life (t½) cannot be calculated.	Interpret as reported	Not specified	Result: Qualitative or narrative result · Molecular form: not reported · Route: ORAL · 59 · Plecanatide · exact product name match · field mismatch · Source: Primary reference linked	Source record

AUC1 record · 0 matched-context · 1 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	Observation Therefore, standard pharmacokinetic parameters such as AUC, maximum concentration (C max ), and half-life (t ½ ) could not be calculated.	Interpret as reported	human	Result: Qualitative or narrative result · Molecular form: ATLPF0030105 · Plecanatide· 12.3 Pharmacokinetics · pk parameter not calculable · Therefore, standard ph... · Source: Primary reference linked	Reference

Cmax1 record · 0 matched-context · 1 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	Observation Therefore, standard pharmacokinetic parameters such as AUC, maximum concentration (C max ), and half-life (t ½ ) could not be calculated.	Interpret as reported	human	Result: Qualitative or narrative result · Molecular form: ATLPF0030105 · Plecanatide· 12.3 Pharmacokinetics · pk parameter not calculable · Therefore, standard ph... · Source: Primary reference linked	Reference

Distribution / Barrier

3 records

What is known about distribution, binding, permeability, or barrier crossing?

Evidence records

Complete canonical measurements and observations attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Matched-context analysis

Quantitative results that may be analysed only with scientifically compatible records.

Reported-result review

Qualitative, narrative, or review-first results interpreted in their source context.

Endpoints in scopePlasma protein binding Vd

Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis

Quantitative results whose endpoint and context must still be matched before analysis.

Interpret as reported

Qualitative, narrative, or review-first findings preserved in source context.

Supporting context only

Reference, label, clinical, or supporting context for interpretation.

Review before analysis

Records whose present structure does not establish a safe analysis role.

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Vd1 record · 0 matched-context · 1 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	Observation Given that plecanatide concentrations following clinically relevant oral doses were not measurable, plecanatide is expected to be minimally distributed in tissues.	Interpret as reported	human	Result: Qualitative or narrative result · Molecular form: ATLPF0030105 · Route: oral · Plecanatide· 12.3 Pharmacokinetics · distribution minimal due to not measurable plasma te... · Source: Primary reference linked	Reference

Plasma protein binding2 records · 0 matched-context · 2 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	Observation Plecanatide exhibited little to no binding to human serum albumin or human α-1-acid glycoprotein.	Interpret as reported	human · plasma	Result: Qualitative or narrative result · Molecular form: ATLPF0030105 · Plecanatide· 12.3 Pharmacokinetics · plasma binding little to no albumin binding text · P... · Source: Primary reference linked	Reference
2	Observation Plecanatide exhibits little to no binding to human serum albumin or human α-1-acid glycoprotein.	Interpret as reported	plasma protein	Result: Qualitative or narrative result · Molecular form: not reported · Route: ORAL · 59 · Plecanatide · exact product name match · field mismatch · Source: Primary reference linked	Source record

Barrier and permeability assay context

PAMPA, Caco-2, MDCK/RRCK, and BBB findings are assay/model contexts under Distribution / Barrier. They should not be read as interchangeable measurements.

PAMPA

artificial membrane

Caco-2

cell monolayer

MDCK

cell monolayer

RRCK

cell monolayer

BBB

barrier evidence

Evidence landscape

7 records

Cross-domain evidence distribution and measurement-level detail; the domain modules above show evidence in context, and every row remains available for audit here.

Evidence landscape

A cross-domain view of evidence volume, scientifically permitted analysis use, and source traceability.

ADMET domain

Eligible when context matches

Interpret as reported

Supporting context only

Review before analysis

Exposure / Absorption

4 evidence records

Distribution / Barrier

3 evidence records

Metabolic & Proteolytic Stability

0 evidence records

Excretion / Persistence

0 evidence records

Toxicity / Safety

0 evidence records

Endpoint distribution

Top evidence-bearing endpoint questions.

Bioavailability

Plasma Protein Binding

Area Under Curve

Max Concentration

Volume Of Distribution

Assay context

Broad context buckets, useful before comparing values.

In vivo / route

Traceability

Reference-link availability for measurement-level audit.

Linked reference

Not linked

All evidence index

Every evidence record remains available for audit and drilldown. Counts describe evidence volume, not confidence.

DomainAnalysis useReferenceMatrix

#	ADMET domain	Endpoint	Reported value	Result type	Analysis use	Assay / model	Condition	Reference
1	Distribution / Barrier Distribution	Plasma Protein Binding	Observation Plecanatide exhibits little to no binding to human serum albumin or human α-1-acid glycoprotein.	Qualitative or narrative result	Interpret as reported	plasma protein	Route: ORAL	Source record Primary reference linked
2	Exposure / Absorption Exposure	Bioavailability	Observation Plecanatide is minimally absorbed with negligible systemic availability following oral administration. Concentrations of plecanatide and its active metabolite in plasma are below the limit of quantitation after an oral dose of 3 mg. Therefore, standard pharmacokinetic parameters such as AUC, maximum concentration (Cmax), and half-life (t½) cannot be calculated.	Qualitative or narrative result	Interpret as reported	Not specified	Route: ORAL	Source record Primary reference linked
3	Exposure / Absorption Exposure	Bioavailability	Observation Plecanatide was minimally absorbed with negligible systemic availability following oral administration.	Qualitative or narrative result	Interpret as reported	human	Route: oral	Reference Primary reference linked
4	Distribution / Barrier Distribution	Volume Of Distribution	Observation Given that plecanatide concentrations following clinically relevant oral doses were not measurable, plecanatide is expected to be minimally distributed in tissues.	Qualitative or narrative result	Interpret as reported	human	Route: oral	Reference Primary reference linked
5	Distribution / Barrier Distribution	Plasma Protein Binding	Observation Plecanatide exhibited little to no binding to human serum albumin or human α-1-acid glycoprotein.	Qualitative or narrative result	Interpret as reported	human · plasma	Not specified	Reference Primary reference linked
6	Exposure / Absorption Exposure	Area Under Curve	Observation Therefore, standard pharmacokinetic parameters such as AUC, maximum concentration (C max ), and half-life (t ½ ) could not be calculated.	Qualitative or narrative result	Interpret as reported	human	Not specified	Reference Primary reference linked
7	Exposure / Absorption Exposure	Max Concentration	Observation Therefore, standard pharmacokinetic parameters such as AUC, maximum concentration (C max ), and half-life (t ½ ) could not be calculated.	Qualitative or narrative result	Interpret as reported	human	Not specified	Reference Primary reference linked

1–7 / 7

Product context

1 products

Product-level route, label, and clinical context that frames peptide-level evidence. A peptide-level summary only; product pages keep the full drilldown.

Summary1 linked product

Linked products: 1
Label context: 1
Clinical trials: 14
Safety label cues: 3

Linked products1 shown

Plecanatide

TRULANCE

Peptide-product match

Reviewed peptide match

Route / product class

oral · Tablet

Clinical context

14 trial records · 13 exact intervention matches · 11 with results · latest 2026-04-07

Label safety context

Label linked · Boxed warning · Contraindications · Adverse reactions

View product

Identity & reference map

7 sources

Reference-level support for checking reported names, sequence notation, and peptide identity agreement.

Summary2 reference groups

Identity type: canonical sequence
Reported notation: 1
Reference groups: 2
Measurements: 7
ATL peptide ID: ATLPC0019952

Identity concordance

Exact reported notation

Reported sequence string matches the current peptide notation.

0 / 7

Parent-residue compatible

Reported notation differs, but resolves to the same parent-residue display.

2 / 7

Different notation

Reported notation does not resolve to the current display sequence.

0 / 7

Source sequence not captured

No source-specific sequence was captured for comparison; this is not interpreted as agreement or disagreement.

5 / 7

Reported sequence notation

Parent-compatible2 references

NDEC(1)ELC(2)VNVAC(1)TGC(2)L

Current identity

NDECELCVNVACTGCL

Reported names

No distinct human-readable aliases are exposed.

Reference map2 reference groups

Reference map

Grouped by reference link, with endpoint scope and reported identity kept visible.

Reference	Supports	Reported identity	Records
Reference Open	DistributionExposure Area Under Curve, Bioavailability, Max Concentration, Plasma Protein Binding +1 more	No reported alias	5 identity 5 evidence
Source record Open	DistributionExposure Bioavailability, Plasma Protein Binding	No reported alias NDEC(1)ELC(2)VNVAC(1)TGC(2)Lparent-compatible	2 identity 2 evidence

Data access & reproducibility

Stable record access, analysis-ready files, and scripted retrieval for reproducing this profile view.

Record scopePublic release

ATL peptide ID: ATLPC0019952
Identity type: canonical sequence
ADMET endpoints: 5
Evidence records: 7
Reference groups: 2
Release view: Public release

Data access

Structured peptide profile

JSON

Peptide-specific profile used by this page, including identity and evidence context.

Open JSON

Peptide catalogue

TSV

Complete frozen peptide table. Filter the ATL peptide ID column locally to isolate this record.

Download catalogue

Measurement catalogue

TSV

Complete frozen measurement table. Join or filter by ATL peptide ID for peptide-level analysis.

Download measurements

Programmatic access

The request returns the same structured peptide record used by this profile. The tabular downloads are complete frozen release tables and should be filtered locally by ATL peptide ID.

Open endpoint

GET /api/v1/peptides/ATLPC0019952

open

curl -sS 'https://admetatlas.scbdd.com/api/v1/peptides/ATLPC0019952' \
  -H 'accept: application/json' \
  -H 'X-Visibility: public_release'

Form

Topology

Modifications

Connections

Representations

Measurements

ATLPF0030105

—

Feature

Positions

Interpretation

Link

Form-level topology

ATLPF0030105

Multiple-disulfide form. Residue-level connection endpoints are shown separately when available.

Not linked

Value

Analysis use

Assay / model

Result context

Reference

Observation

Plecanatide was minimally absorbed with negligible systemic availability following oral administration.

Interpret as reported

human

Result: Qualitative or narrative result · Molecular form: ATLPF0030105 · Route: oral · Plecanatide· 12.3 Pharmacokinetics · bioavailability negligible systemic availability tex... · Source: Primary reference linked

Reference

Observation

Plecanatide is minimally absorbed with negligible systemic availability following oral administration. Concentrations of plecanatide and its active metabolite in plasma are below the limit of quantitation after an oral dose of 3 mg. Therefore, standard pharmacokinetic parameters such as AUC, maximum concentration (Cmax), and half-life (t½) cannot be calculated.

Interpret as reported

Not specified

Result: Qualitative or narrative result · Molecular form: not reported · Route: ORAL · 59 · Plecanatide · exact product name match · field mismatch · Source: Primary reference linked

Source record

Value

Analysis use

Assay / model

Result context

Reference

Observation

Therefore, standard pharmacokinetic parameters such as AUC, maximum concentration (C max ), and half-life (t ½ ) could not be calculated.

Interpret as reported

human

Result: Qualitative or narrative result · Molecular form: ATLPF0030105 · Plecanatide· 12.3 Pharmacokinetics · pk parameter not calculable · Therefore, standard ph... · Source: Primary reference linked

Reference

Value

Analysis use

Assay / model

Result context

Reference

Observation

Therefore, standard pharmacokinetic parameters such as AUC, maximum concentration (C max ), and half-life (t ½ ) could not be calculated.

Interpret as reported

human

Reference

Value

Analysis use

Assay / model

Result context

Reference

Observation

Given that plecanatide concentrations following clinically relevant oral doses were not measurable, plecanatide is expected to be minimally distributed in tissues.

Interpret as reported

human

Result: Qualitative or narrative result · Molecular form: ATLPF0030105 · Route: oral · Plecanatide· 12.3 Pharmacokinetics · distribution minimal due to not measurable plasma te... · Source: Primary reference linked

Reference

Value

Analysis use

Assay / model

Result context

Reference

Observation

Plecanatide exhibited little to no binding to human serum albumin or human α-1-acid glycoprotein.

Interpret as reported

human · plasma

Result: Qualitative or narrative result · Molecular form: ATLPF0030105 · Plecanatide· 12.3 Pharmacokinetics · plasma binding little to no albumin binding text · P... · Source: Primary reference linked

Reference

Observation

Plecanatide exhibits little to no binding to human serum albumin or human α-1-acid glycoprotein.

Interpret as reported

plasma protein

Result: Qualitative or narrative result · Molecular form: not reported · Route: ORAL · 59 · Plecanatide · exact product name match · field mismatch · Source: Primary reference linked

Source record

ADMET domain

Endpoint

Reported value

Result type

Analysis use

Assay / model

Condition

Reference

Distribution / Barrier

Distribution

Plasma Protein Binding

Observation

Plecanatide exhibits little to no binding to human serum albumin or human α-1-acid glycoprotein.

Qualitative or narrative result

Interpret as reported

plasma protein

Route: ORAL

Source record

Primary reference linked

Exposure / Absorption

Exposure

Bioavailability

Observation

Qualitative or narrative result

Interpret as reported

Not specified

Route: ORAL

Source record

Primary reference linked

Exposure / Absorption

Exposure

Bioavailability

Observation

Plecanatide was minimally absorbed with negligible systemic availability following oral administration.

Qualitative or narrative result

Interpret as reported

human

Route: oral

Reference

Primary reference linked

Distribution / Barrier

Distribution

Volume Of Distribution

Observation

Given that plecanatide concentrations following clinically relevant oral doses were not measurable, plecanatide is expected to be minimally distributed in tissues.

Qualitative or narrative result

Interpret as reported

human

Route: oral

Reference

Primary reference linked

Distribution / Barrier

Distribution

Plasma Protein Binding

Observation

Plecanatide exhibited little to no binding to human serum albumin or human α-1-acid glycoprotein.

Qualitative or narrative result

Interpret as reported

human · plasma

Not specified

Reference

Primary reference linked

Exposure / Absorption

Exposure

Area Under Curve

Observation

Therefore, standard pharmacokinetic parameters such as AUC, maximum concentration (C max ), and half-life (t ½ ) could not be calculated.

Qualitative or narrative result

Interpret as reported

human

Not specified

Reference

Primary reference linked

Exposure / Absorption

Exposure

Max Concentration

Observation

Therefore, standard pharmacokinetic parameters such as AUC, maximum concentration (C max ), and half-life (t ½ ) could not be calculated.

Qualitative or narrative result

Interpret as reported

human

Not specified

Reference

Primary reference linked

Reference

Supports

Reported identity

Records

Reference

Open

DistributionExposure

Area Under Curve, Bioavailability, Max Concentration, Plasma Protein Binding +1 more

No reported alias

5 identity

5 evidence

Source record

Open

DistributionExposure

Bioavailability, Plasma Protein Binding

No reported alias

NDEC(1)ELC(2)VNVAC(1)TGC(2)Lparent-compatible

2 identity

2 evidence